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A b s t r A c t
Over the recent years it has been clearly demonstrated that reperfusion by primary 
coronary angioplasty in patients with ST-elevation myocardial infarction (STEMI) is 
the treatment of choice. For hospitals without the capacity of performing primary an-
gioplasty, reperfusion with on-site thrombolysis or transportation of the patient to an-
other institution for primary percutaneous coronary intervention (PCI) within a tight 
timeframe are the alternative options. For the latter strategy, an organized network 
of centers is needed to rapidly transfer STEMI patients for primary PCI. Although 
transferring STEMI patients for primary PCI is superior reperfusion therapy in com-
parison to on-site thrombolysis, there are concerns, regarding time delays of transfer 
in daily practice, which is a major drawback of this therapeutic strategy as delays of 
>120 minutes from first medical contact to primary PCI negate the advantage of pri-
mary PCI over thrombolysis.
The narrow time interval (<90-120 min) that is mandatory for the superiority of pri-
mary PCI, could be extended if a pharmacoinvasive strategy (fibrinolysis followed by 
routine “early” angioplasty of the culprit artery) was chosen. Convincing results from 
trials such as TRANSFER-AMI, FAST-MI, GRACIA-2, WEST-MI, CARESS-
AMI, NORDISTEMI and STREAM indicated that combined use of thrombolysis 
followed by PCI after >3 hours to 6-12 hours in order to neutralize the thrombolysis 
associated complications of PCI and allow full action of antiplatelet and antithrom-
botic agents, had comparable efficacy in comparison to primary PCI regarding early 
and 1-year survival. This appears to be an effective alternative option for the treat-
ment of STEMI patients, at least for those hospitals wherebimmediate PCI is unavail-
able, an issue which is particularly relevant for patients suffering a STEMI on remote 
areas or islands.
I n t r o d u c t I o n
Over the last decade there were published the results from several trials (DA-
NAMI-2,1 PRAGUE-1,2 and PRAGUE-2,3 AIR–PAMI4), which compared on-site 
thrombolysis with primary PCI (defined as angioplasty and/or stenting without prior 
or concomitant fibrinolytic therapy), showed that primary percutaneous coronary 
intervention (PCI) is the cornerstone for effective treatment of ST-elevation myocar-
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dial infarction (STEMI) patients, when it can be performed 
by an experienced team. Combined data from those trials put 
emphasis on the superiority of primary PCI in significantly 
decreasing the composite endpoint of nonfatal myocardial 
infarction, stroke or death compared to fibrinolysis5 along with 
superior effectiveness of the former in restoration of vessel 
patency, less re-occlusion, improved residual left ventricular 
function and better clinical outcome.6
The fact that many hospitals lack facilities for primary PCI, 
underlies the need for a well organized system of transport in 
order to safely and within acceptable time limits transfer such 
patients to PCI capable centers. However, optimal time limits 
of transfer cannot always be achieved and several trials tested 
the strategy of facilitated PCI. Several trials have indicated 
that pharmacoinvasive reperfusion before mechanical reca-
nalization in combination with the appropriate time interval 
between the two therapies could be an alternative strategy for 
treating STEMI patients.
r e p e r f u s I o n  s t r A t e g I e s  A n d 
p r I m A r y  p c I  d e l A y s  t I m e s  I n  s t e m I
Current European Society of Cardiology (ESC) guidelines7 
indicate primary PCI as the preferred pathway of treatment of 
STEMI patients. In PCI capable centers the aim is to achieve 
a delay of ≤60 min from presentation in the hospital to wire 
passage into the culprit artery (door to balloon delay). Patients 
referred to a non-PCI capable center should be transferred 
for primary PCI with a delay time (first medical contact -FMC 
to wire passage into the culprit artery) of ≤90 min while this 
delay should be reduced to ≤60 min in high risk patients with 
large anterior infarction and in early presenters (within 2 hours 
from symptom onset).8 These target delays for implementa-
tion of primary PCI are quality indicators and they differ from 
the maximal PCI-related delay of 120 min, which is useful in 
selecting primary PCI over immediate thrombolysis as the 
preferred mode of reperfusion.9
In case that primary PCI cannot be performed within the 
aforementioned time limits, thrombolysis is the alternative 
reperfusion therapy within ≤30 min delay (time delay from 
FMC to needle).The patient can then be transferred to a PCI 
capable hospital in order to undergo rescue PCI in case of 
failed fibrinolysis, or angiography and delayed PCI if required, 
in case of successful fibrinolysis, in a time window of 3-24 
hours. In the same wavelength, recently published guidelines 
of ACCF/AHA for the management of STEMI,9 emphasize 
on primary PCI as the recommended method of treatment 
provided it can be performed within ≤90 min (from FMC-
to-device time) in case that the patient is transferred directly 
to a PCI capable hospital, while FMC-to-device time should 
be ≤120 min if the patient is transferred from a non-PCI to 
a PCI capable hospital. In case that primary PCI cannot be 
performed within 120 minutes from the arrival to a non-PCI 
capable hospital, thrombolysis should be administered within 
≤30 minutes of hospital arrival.
PCI-related time delay is the difference between the door-
to-balloon minus the door-to-needle time. From randomized 
trials it was calculated that PCI-related time delay that can 
decrease the effectiveness of mechanical restoration of vessel 
patency over fibrinolysis varies between 60 and 110 minutes.10,11 
Pinto et al12 calculated the mean PCI-related time delay where 
two reperfusion strategies appeared to have equal mortality 
rates and that time was found to be 114 minutes. According to 
Boersma and the Primary Coronary Angioplasty vs Thromboly-
sis (PCAT)-2 Trialists’ Collaborative Group,13 the advantage 
tAble 1. List of trials’ acronyms used in the text.
1. AIR-PAMI: Air-Primary Angioplasty in Myocardial 
Infarction.
2. ASSENT-4 PCI: Assessment of the Safety and Efficacy of 
a New Treatment Strategy with Percutaneous Coronary 
Intervention.
3. CARESS-AMI: Combined Abciximab REteplase Stent Study 
in Acute Myocardial Infarction
4. DANAMI: Danish Multicenter Randomized Trial on 
Thrombolytic Therapy Versus Acute Coronary Angioplasty in 
Acute Myocardial Infarction.
5. FAST-AMI: French Registry on Acute ST-Elevation 
Myocardial Infarction.
6. FINESSE: Assessment of the Safety and Efficacy of a New 
Treatment Strategy with Percutaneous Coronary Intervention.
7. GRACIA: GRupo de Analisis de la Cardiopatia Isquemica 
Aguda.
8. LIMI: Limburg Interventional Myocardial Infarction.
9. NORDISTEMI: NORwegian study on DIstrict treatment of 
ST-Elevation Myocardial Infarction.
10. NMRI: National Registry for Myocardial Infarction.
11. PRAGUE: PRimary Angioplasty in patients transferred from 
General community hospitals to specialized PTCA Units with 
or without Emergency thrombolysis.
12.  STREAM: Strategic Reperfusion Early after Myocardial 
infarction.
13. TRANSFER-AMI: Trial of Routine Angioplasty and 
Stenting after Fibrinolysis to Enhance Reperfusion in Acute 
Myocardial Infarction.
14. WEST: Which Early ST-elevation myocardial infarction 
Therapy.
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of primary PCI over fibrinolytic therapy may remain with a 
PCI related delay of up to 120 minutes. However, this time 
delay varies according to age, time from symptom onset and 
infarct location.
t r A n f e r r I n g  s t e m I  p A t I e n t s  
f o r  p r I m A r y  p c I .  A d v A n t A g e s  
A n d  d r A w b A c K s
The concept of transferring patients with STEMI for pri-
mary PCI was supported by a number of trials. In the Danish 
Multicenter Randomized Trial on Thrombolytic Therapy 
Versus Acute Coronary Angioplasty in Acute Myocardial 
Infarction (DANAMI-2),1 1.572 patients with STEMI were 
randomly assigned to on-site thrombolysis with accelerated 
tissue plasminogen activator or primary PCI at 24 hospitals in 
Denmark. Patients who were randomized to primary PCI at 
referral centers were transferred to one of 5 invasive centers, 
provided that the transfer would likely take up to 3 hours. 
The DANAMI-2 trial was stopped early because of an ap-
proximately 40% lower incidence of the primary end point of 
recurrent myocardial infarction, disabling stroke, or death at 
30 days with primary PCI compared with fibrinolysis (8.5% 
vs 14.2%; p=0.002). This initial experience has shown that an 
organized network of centers could rapidly and safely transfer 
STEMI patients for primary PCI.
In the PRimary Angioplasty in patients transferred from 
General community hospitals to specialized PTCA Units with 
or without Emergency thrombolysis, (PRAGUE) study,2 the 
safety and feasibility of inter-hospital transfer of patients 
with STEMI in the Czech Republic was evaluated. A total of 
300 patients were randomly assigned to three groups: group 
A (99 patients) received intravenous streptokinase; group B 
(100 patients) received streptokinase with immediate trans-
fer to an invasive center for subsequent PCI; and group C 
(101 patients) was transported to an invasive center without 
receiving fibrinolytic therapy. Transfer was well tolerated, 
tAble 2. Occurrence of composite primary endpoint in different studies of transfer PCI, facilitated-PCI and thrombolysis 
followed by routine angioplasty.
study 
(number of patients)
transfer pcI
pcI included  
in initial treatment
pcI not included  
in initial treatment
p favours
(DANAMI-2)1 8.5% 14.2% p=0.002 PCI
(PRAGUE-1)2 8% 23% p<0.02 PCI
(PRAGUE-2)3-All 6.8% 10.0% p<0.12 PCI
(PRAGUE-2)3 <3h 7.3% 7.4% p=NS NS
(PRAGUE-2)3 >3h 6.0% 15.3% p<0.02 PCI
AIR-PAMI4 8.4% 13.6% p=0.33 PCI
facilitated pcI
study primary pcI facilitated pcI p favours
ASSENT-4 PCI18 13% 19% p=0.0045 Primary PCI
FINESSE19 10.7% 9.8% p=0.55 NS
thrombolysis followed by routine angioplasty
study routine pcI post thrombolysis rescue/delayed pcI p favours
TRANSFER-AMI20 11.0% 17.2% p=004 Routine PCI
CARESS24 4.4% 10.7% p=004 Routine PCI
NORDISTEMI25 6.0% 16.0% p=0.01 Routine PCI
routine pcI post thrombolysis primary pcI p favours
FAST-MI registry21 4.3% 5.0% p=NS NS
GRACIA-223 10% 12% p=0.57 NS
STREAM26 12.4% 14.3% p=0.21 NS
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with rare nonfatal complications and no deaths. The primary 
composite end point (re-infarction, stroke, or death at 30 days) 
was reduced across groups A, B, and C (23%, 15%, and 8%, 
respectively; p <0.02).
The following PRAGUE-2 trial3 randomized 850 STEMI 
patients from community hospitals in Czech Republic to 
on-site fibrinolysis with streptokinase or transfer to invasive 
centers for primary PCI. There was a modest trend toward 
reduction in the primary end point of 30-day mortality with 
primary PCI versus streptokinase (6.8% vs 10.0%; p <0.12). 
Analysis of a pre-specified subgroup of patients who presented 
within 3 hours of symptom onset showed no mortality ben-
efit with transfer for PCI (7.3% vs 7.4%), whereas patients 
who presented within 3 to 12 hours of symptom onset had a 
significant reduction in mortality (6.0% vs 15.3%; p <0.02). 
Therefore, the PRAGUE-2 results confirm the feasibility of 
transferring STEMI patients for primary PCI, but also suggest 
that transfer for primary PCI may primarily benefit patients 
who present late after symptom onset.
In the AIR-PAMI trial,4 138 STEMI patients were rand-
omized to receive either on site thrombolysis (67 patients) or 
to be immediately transferred for primary PCI (71 patients).
The time from arrival to treatment was delayed in the transfer 
group (155 vs 51 min, p <0.0001), mainly due to the initiation 
of transfer (43 min) and transport time (26 min). Primary PCI 
had a non-significant lower risk of re-infarction, disabling 
stroke, or death at 30 days (8.4% vs 13.6%; p=0.33).
Meta-analyses 5 of results from fibrinolysis versus pri-
mary PCI trials, included data from 5 trials (DANAMI-2, 
PRAGUE-1 and -2, AIR-PAMI, and the Limburg Interven-
tion/MI trial) that compared on-site fibrinolysis with immedi-
ate transfer for primary PCI. Combined data from these trials 
indicate that transfer for primary PCI was associated with a 
significant decrease in the composite end point of nonfatal 
myocardial infarction, stroke, or death compared with fi-
brinolysis. These cumulative results underscore the concept 
that transferring STEMI patients for primary PCI appears 
to be a superior reperfusion strategy compared with on-site 
fibrinolysis at a non-PCI capable hospital.
However, the key point for successful reperfusion with 
primary PCI is short delay times in combination with a cardiac 
catheterization laboratory available 24 hours/7 days including 
experienced interventional cardiologists and supporting staff. 
For this purpose, not only a well organized medical system is 
mandatory, but also a well functioning network of centers for 
safe and rapid STEMI patient transportation. Short delay times 
for primary PCI is a task not always easy to achieve. Miedema 
et al14 indicated that the greater delays from FMC at the refer-
ral hospital until arrival at the catheterization laboratory are 
observed when there is diagnostic dilemma, non-diagnostic 
ECG, hemodynamic compromise or bad weather conditions. 
In this particular study of 2034 patients transferred for primary 
PCI, only 30.4% were treated with primary PCI in ≤90 min 
and 65.7% in ≤120 min. Data from the National Registry for 
Myocardial Infarction (NRMI)15 indicated that inter-hospital 
transfer from a non-PCI to a PCI-capable hospital is associated 
with low rates of door-to-balloon within time limits (4.2% for 
door-to-balloon <90 min, 16.2% for door-to-balloon <2 h).
In addition, Wang et al16 indicated that STEMI patients 
requiring inter-hospital transfer for primary PCI had longer 
door-to-balloon times in comparison with direct arrival STEMI 
patients (median 149 min vs 79 min p<0.001) and few received 
PCI at ≤90 min (10% vs 63% p<0.001). Pinto et al17 in an 
analysis from NRMI-2,-3,-4 and 5, reported that PCI-related 
delays are extensive among patients transferred for primary 
PCI and are associated with poorer outcomes. When transfer 
delays for primary PCI exceeded 120 min from FMC, there 
was no advantage of primary PCI over thrombolysis. As delays 
of >120 min and >90 min occurred in nearly half and in 68% 
of the patients respectively, there was no difference in mor-
tality (5.7% vs 6.1%), in the composite end-point of death or 
myocardial infarction (6.7% vs 8.6%) and death, myocardial 
infarction or stroke (7.1% vs 9.3%).
t h r o m b o l y s I s  f o l l o w e d  
b y  r o u t I n e  A n g I o p l A s t y
From the aforementioned data, it is clear that time to treat-
ment with primary PCI is an important determinant of the clini-
cal outcome of STEMI patients. Thus, inter-hospital transfer 
to a PCI capable hospital is the strategy of choice under the 
premise that primary PCI can be performed within 120 min 
from FMC. Fibrinolytic therapy should be administered in the 
absence of contraindications, if the goal of less than 120 min 
delay cannot be achieved. The term facilitated PCI was used to 
describe a combined therapy of full- or half-dose fibrinolysis in 
order to maximize the initial reperfusion rate and immediate 
transfer for PCI within 90-120 min. However, the Assesment 
of the Safety and Efficacy of a New Treatment Strategy with 
Percutaneous Coronary Intervention (ASSENT) -4 PCI18 and 
Facilitated Intervention with Enhanced Reperfusion Speed to 
Stop Events (FINESSE)19 trials failed to show clinical benefit 
over primary PCI in STEMI patients, thus this strategy should 
be avoided. Failure of facilitated PCI may at least have been 
accounted for by thrombolysis-induced platelet activation, 
intra-plaque hemorrhage of the culprit lesion and increased 
bleeding risk with resulting propensity for acute complications 
during PCI. As discussed below, these shortcomings of facili-
tated PCI can be overcome by performing immediate PCI only 
in patients with failed thrombolysis, i.e., for rescue purposes, 
while delaying PCI in successfully thrombolysed patients.
The term pharamacoinvasive strategy is used to describe the 
administration of thrombolysis, either in a pre-hospital setting 
(ambulance) or at a non-PCI capable hospital, followed by the 
immediate transfer for early PCI. Ideal patients for receiving 
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fibrinolysis as initial therapy, are early presenters (<2-3h from 
symptoms onset) with low bleeding risk and prolonged time 
delay to PCI. In order to achieve beneficial effect of primary-
PCI over thrombolysis, PCI-related time might be extended 
if pharmaconvasive treatment with fibrinolysis, followed by 
routine angioplasty during the following hours, is selected. 
Results from several trials such as TRANSFER-AMI, FAST-
MI, GRACIA-2, WEST-MI, CARESS-AMI, NORDSTEMI 
and STREAM are rather convincing because of overall con-
sistency in their results.
In the Trial of Routine Angioplasty and Stenting after 
Fibrinolysis to Enhance Reperfusion in Acute Myocardial 
Infarction trial (TRANSFER-AMI) trial,20 1.059 high-risk 
patients who had a STEMI and who were receiving fibrinolytic 
therapy at centers that did not have the capability of per-
forming PCI, were randomized to either standard treatment 
(including rescue PCI, if required, or delayed angiography) 
or a strategy of immediate transfer to another hospital and 
PCI within 6 hours after fibrinolysis. All patients received 
aspirin, tenecteplase and heparin or enoxaparin; concomitant 
clopidogrel was recommended. The primary end-point was the 
composite of death, reinfarction, recurrent ischemia, new or 
worsening congestive heart failure, or cardiogenic shock within 
30 days. PCI was performed in 67.4% of the patients assigned 
to standard treatment a median of 21.9 hours after randomiza-
tion and in 84.9% of the patients assigned to routine early PCI 
a median of 3.9 hours after administration of tenecteplase. 
At 30 days, the primary end point occurred in 11.0% of the 
patients who were assigned to routine early PCI and in 17.2% 
of the patients assigned to standard treatment (relative risk 
with early PCI, 0.64; 95% confidence interval, 0.47 to 0.87; p 
= 0.004). There were no significant differences between the 
groups in the incidence of major bleeding.
The findings described in the TRANSFER-AMI confirmed 
the almost one year ago earlier published results of the French 
Registry on Acute ST-Elevation Myocardial Infarction (FAST-
MI)21 registry, a report of daily practice of STEMI treatment in 
France. The purpose of the study was to assess contemporary 
outcomes in STEMI patients, with specific emphasis on com-
paring a pharmacoinvasive strategy (thrombolysis followed by 
routine angiography) with primary PCI. Of the thrombolysis 
group 96% underwent subsequent angiography, with 84% un-
dergoing PCI (58% within 24 hours of receiving thrombolysis). 
In the thrombolysis cohort the mean time interval from lysis to 
PCI was 290 minutes and in the primary PCI group 300 min. 
In-hospital mortality was 5.0% in patients with primary PCI 
and 4.3% in those with thrombolysis. One-year survival was 
94% for thrombolysis and 93% for primary PCI. Thus, when 
used early after the onset of symptoms, a pharmacoinvasive 
strategy that combined thrombolysis with a liberal use of PCI 
yielded early and 1-year survival rates that were comparable 
to those of primary PCI. Finally, when analyzed according to 
the timing of PCI after thrombolysis (according to quartiles 
of time delay from thrombolysis to PCI), 30-day mortality 
was 4.1% in the first and second quartiles (time from lysis to 
PCI=220 minutes) vs 3.6% in the third and fourth quartiles. 
Notably, mortality tended to be lower with increasing time 
from thrombolysis when PCI was performed on a systematic 
fIgure 1. Flowchart of suggested reperfusion strategies in STEMI patients.
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basis, whereas it tended to increase with increasing time from 
thrombolysis when PCI was performed as a rescue procedure.
The Which Early ST-elevation myocardial infarction 
Therapy (WEST)22 trial demonstrated that thrombolytic 
therapy followed by systematic PCI within 24 hours yielded 
results comparable to those of primary PCI. In the GRupo 
de Analisis de la Cardiopatia Isquemica Aguda (GRACIA)-2 
trial23 a total of 212 STEMI patients were randomized to full 
tenecteplase followed by stenting within 3–12 hours of ran-
domization (early routine post-fibrinolysis angioplasty; 104 
patients), or to undergo primary stenting with abciximab within 
3 hours of randomization (primary angioplasty; 108 patients). 
The primary endpoints were epicardial and myocardial reper-
fusion (i.e., TIMI 3 epicardial flow and resolution of the initial 
sum of ST-segment elevation >70%) as well as the extent of 
left ventricular myocardial damage, as determined by means 
of the infarct size and the 6-week left ventricular function. 
Early routine post-fibrinolysis angioplasty resulted in higher 
frequency (21 vs. 6%, P=0.003) of complete epicardial and 
myocardial reperfusion following angioplasty. Both groups 
were similar regarding infarct size (area under the curve of 
CK-MB: 4613±3373 vs 4649±3632 mg/L/h, P=0.94); 6-week 
left ventricular function (ejection fraction: 59.0±11.6 vs. 
56.2±13.2%, P=0.11; end-systolic volume index: 27.2±12.8 
vs. 29.7±13.6, P=0.21); major bleeding (1.9 vs 2.8%, P=0.99) 
and 6-month cumulative incidence of the primary endpoint 
(10% vs 12%, P=0.57; relative risk: 0.80; 95% confidence 
interval: 0.37–1.74).
The results of the Combined Abciximab REteplase Stent 
Study (CARESS) trial24 confirmed that a policy of systematic 
PCI after thrombolysis was superior to a policy of PCI re-
stricted to cases needing rescue based on symptoms and lack 
of resolution of ST elevation. In this trial the primary outcome 
(a composite of death, re-infarction, or refractory ischemia) 
at 30 days, occurred in 13 patients (4.4%) in the immediate 
PCI group compared with 32 (10.7%) in the standard care/
rescue PCI group (hazard ratio 0·40; 95% CI 0.21–0.76, log 
rank p=0.004) and the time interval between thrombolysis 
and PCI was 135 minutes.
In the NORDSTEMI25 trial (NORwegian study on DIstrict 
treatment of ST-Elevation Myocardial Infarction), a total of 
266 patients with acute STEMI with more than 90-min transfer 
delays to PCI were treated with tenecteplase, aspirin, enoxa-
parin and clopidogrel and randomized to immediate transfer 
for PCI or to standard management in the local hospitals with 
early transfer, only if indicated for rescue or ischemia-driven 
PCI. The median time from fibrinolysis to PCI was 163 min 
(2.7 hours) in the early invasive group. The composite of death, 
reinfarction, or stroke at 12 months was significantly reduced 
in the early invasive compared with the conservative group 
(6% vs 16%, hazard ratio: 0.36, 95% confidence interval: 0.16 
to 0.81, p=0.01).
Very recently, in the Strategic Reperfusion Early after 
Myocardial infarction (STREAM) trial,26 1892 patients with 
STEMI who presented within 3 hours from symptom onset 
and in whom primary PCI could not be performed within 60 
minutes, were randomized to undergo either primary PCI 
or fibrinolytic therapy with tenecteplase, clopidogrel and 
enoxaparin before transportation to a PCI-capable hospital. 
Angiography was performed 6-24 hours after randomization 
unless fibrinolysis failed and emergency coronary angiography 
was performed as soon as possible. The primary endpoint 
was a composite of death, shock, congestive heart failure, or 
re-infarction up to 30 days. The primary endpoint occurred 
in 12.4% of fibrinolysis patients and in 14.3% in the primary 
PCI group (relative risk in the fibrinolysis group 0.86; 95% 
CI 0.68-1.09 p=0.21). Emergency coronary angiography was 
performed in 36.3% of patients after thrombolysis. The rest of 
the patients from the thrombolysis group underwent angiogra-
phy within 17 hours after randomization. Rates of intracranial 
hemorrhage were higher in the thrombolysis group (1% vs 
0.2% p=0.04), while rates of non-intracranial bleeding were 
similar in the two groups. The results of this trial indicated 
that pre-hospital or early thrombolysis followed by coronary 
angiography in patients with STEMI who could not undergo 
primary PCI within 1 hour from first medical contact, has 
similar efficacy in comparison with primary PCI. However, 
fibrinolysis was related with a slight increase in the risk of 
intracranial bleeding.
Finally it is now clearly established that in the pharmacoin-
vasive strategy of treating STEMI patients, the time window 
between fibrinolysis and PCI is crucial regarding the efficacy 
of such a strategy as longer delay is associated with reduced 
risk of bleeding and better outcome. The narrow time window 
between facilitated fibrinolysis and immediate PCI (90 min 
in ASSENT and 104 min in FINESSE) seems to have had a 
negative impact on hemorrhagic events, while results are better 
according to aforementioned trials if PCI is performed later 
after initial fibrinolysis, i.e., within a time-frame of a >3 and 
up to 24 hour timing at amelioration of the pro-hemorrhagic 
and pro-thrombotic effects of thrombolysis.
c o n c l u s I o n
Primary PCI is the established method for treatment of 
STEMI patients, however there are some drawbacks regarding 
the achievement of strict time limits for this task. Combined 
pharmacoinvasive strategy in an appropriate time window 
could be an efficient therapeutic option especially for hospitals 
that lack facilities for primary PCI.
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